{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:04:38Z","timestamp":1758053078906,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.crad.2023.03.014","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T11:32:13Z","timestamp":1680694333000},"page":"518-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biochemically recurrent prostate cancer: rationalisation of the approach to imaging"],"prefix":"10.1016","volume":"78","author":[{"given":"H.","family":"Briody","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Morrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.crad.2023.03.014_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.10.017","article-title":"Prostate cancer recurrence in patients with negative or equivocal conventional imaging: a role for (18)F-fluciclovine-PET\/CT in delineating sites of recurrence and identifying patients with oligometastatic disease","volume":"39","author":"Kim","year":"2021","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.crad.2023.03.014_bib2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0022-5347(05)66452-X","article-title":"Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?","volume":"165","author":"Amling","year":"2001","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.crad.2023.03.014_bib3","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.juro.2015.12.075","article-title":"Standardizing the definition of biochemical recurrence after radical prostatectomy\u2014what prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression?","volume":"195","author":"Toussi","year":"2016","journal-title":"J Urol"},{"issue":"24","key":"10.1016\/j.crad.2023.03.014_bib4","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.crad.2023.03.014_bib5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00330-009-1647-4","article-title":"Imaging of prostate cancer local recurrences: why and how?","volume":"20","author":"Rouviere","year":"2010","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.crad.2023.03.014_bib6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.juro.2014.05.088","article-title":"Low detectable prostate specific antigen after radical prostatectomy\u2014treat or watch?","volume":"192","author":"Koulikov","year":"2014","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.crad.2023.03.014_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clon.2020.01.003","article-title":"Salvage radiotherapy for prostate cancer","volume":"32","author":"Rans","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.crad.2023.03.014_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13014-019-1383-0","article-title":"Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice","volume":"14","author":"Panje","year":"2019","journal-title":"Radiat Oncol"},{"issue":"11","key":"10.1016\/j.crad.2023.03.014_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.026","article-title":"Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng\/ml following prostatectomy: how much information can conventional imaging provide?","volume":"34","author":"Vargas","year":"2016","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.crad.2023.03.014_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","article-title":"A systematic review on the role of imaging in early recurrent prostate cancer","volume":"2","author":"De Visschere","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.crad.2023.03.014_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clon.2009.10.015","article-title":"A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence","volume":"22","author":"Beresford","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"3","key":"10.1016\/j.crad.2023.03.014_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1464-410X.2004.04927.x","article-title":"Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?","volume":"94","author":"Gomez","year":"2004","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.crad.2023.03.014_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.crad.2023.03.014_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/rg.2019180079","article-title":"Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread","volume":"39","author":"Barbosa","year":"2019","journal-title":"RadioGraphics"},{"issue":"3","key":"10.1016\/j.crad.2023.03.014_bib15","first-page":"245","article-title":"Prostate cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.crad.2023.03.014_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/pros.21420","article-title":"Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum","volume":"72","author":"Briganti","year":"2012","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.crad.2023.03.014_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.crad.2023.03.014_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.euf.2017.11.001","article-title":"Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy\u2014a systematic review","volume":"5","author":"Sandgren","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"10260","key":"10.1016\/j.crad.2023.03.014_bib19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.crad.2023.03.014_bib20","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.crad.2023.03.014_bib21","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.juro.2009.08.027","article-title":"Radiation therapy after radical prostatectomy: impact on metastasis and survival","volume":"182","author":"Boorjian","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.crad.2023.03.014_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.723536","article-title":"A multi-institutional analysis of prostate cancer patients with or without 68Ga-PSMA PET\/CT prior to salvage radiotherapy of the prostatic fossa","volume":"11","author":"Schmidt-Hegemann","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.crad.2023.03.014_bib23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.eururo.2014.09.019","article-title":"Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy","volume":"67","author":"Brockman","year":"2015","journal-title":"Eur Urol"},{"issue":"23","key":"10.1016\/j.crad.2023.03.014_bib24","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.crad.2023.03.014_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.crad.2023.03.014_bib26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:47:34Z","timestamp":1757868454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926023001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0009926023001356"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2023.03.014","relation":{},"ISSN":["0009-9260"],"issn-type":[{"type":"print","value":"0009-9260"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemically recurrent prostate cancer: rationalisation of the approach to imaging","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2023.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}